Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era.

@article{Oefelein2002ClinicalPO,
  title={Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era.},
  author={Michael G. Oefelein and Vincent S Ricchiuti and Phill Conrad and Howard Goldman and Donald G Bodner and Martin I. Resnick and Allen D. Seftel},
  journal={Urology},
  year={2002},
  volume={60 1},
  pages={120-4}
}
OBJECTIVES To further characterize and identify novel predictors of androgen-independent prostate cancer (AIPC) and survival in the prostate-specific antigen (PSA) era. METHODS A total of 184 consecutive patients with prostate cancer receiving chronic androgen suppression were assessed for the development of AIPC and overall survival. RESULTS The median time to development of AIPC was 44 months (Stage M+ = 24 months; Stage M0 = 63 months, P = 0.000001). The 10-year overall survival rate for… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Similar Papers

Loading similar papers…